Bristol-Myers files for Japanese approval of first all-oral hep C treatment; Novogen, Yale tackle ovarian cancer drug delivery together;

> Bristol-Myers Squibb ($BMY) filed with Japanese health regulators to approve its all-oral hepatitis C treatment, the first of its kind. Story

> Novogen and Yale launched a joint venture to develop treatments for ovarian cancer that use a delivery model created by a Yale professor. More

> Zogenix entered a development and option agreement with Altus Formulation for Zogenix's extended-release hydrocodone and Altus' delivery platform. More

> Aphios won a U.S. patent for its nanoencapsulated oral delivery platform for cannabinoids to treat pain in cancer and AIDS patients. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.